Panel Discussion: Cracking the ‘Clean Target’ Challenge with Smarter Selection Strategies to Uncover Safe & Novel Targets
- What defines a ‘clean’ target in practice, and how should we balance prevalence, selectivity, and heterogeneity risks?
- How can emerging technologies like proteomics, spatial biology, and AI improve prediction of protein expression, localisation, and off-tumour toxicity risk?
- How can the field move beyond a limited pool of validated targets while generating robust preclinical data to de-risk novel target investment?